XNASNRSN
Market cap29mUSD
Dec 24, Last price
1.26USD
1D
0.80%
1Q
5.00%
IPO
-60.75%
Name
Neurosense Therapeutics Ltd
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
0k
Net income
-10m
L-9.73%
CFO
-8m
L+11.42%
Profile
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | 12,146 | 13,641 | 5,587 | ||
Unusual Expense (Income) | |||||
NOPBT | (12,146) | (13,641) | (5,587) | ||
NOPBT Margin | |||||
Operating Taxes | (1,143) | (1,546) | |||
Tax Rate | |||||
NOPAT | (12,146) | (12,498) | (4,041) | ||
Net income | (10,107) -9.73% | (11,197) 348.78% | (2,495) -11.81% | ||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 3,970 | 3,870 | 9,864 | ||
BB yield | -37.08% | -27.57% | -206.58% | ||
| Debt | |||||
Debt current | 69 | 64 | |||
Long-term debt | 215 | 358 | 1,828 | ||
Deferred revenue | |||||
Other long-term liabilities | 1,518 | 218 | |||
Net debt | (2,378) | (6,691) | (9,235) | ||
| Cash flow | |||||
Cash from operating activities | (8,452) | (7,586) | (1,539) | ||
CAPEX | (29) | (70) | (17) | ||
Cash from investing activities | 3,468 | (3,541) | (17) | ||
Cash from financing activities | 3,895 | 3,695 | 11,902 | ||
FCF | (11,604) | (12,785) | (4,047) | ||
| Balance | |||||
Cash | 2,640 | 7,090 | 11,063 | ||
Long term investments | 22 | 23 | |||
Excess cash | 2,662 | 7,113 | 11,063 | ||
Stockholders' equity | (32,066) | 5,619 | 9,006 | ||
Invested Capital | 31,852 | 429 | 1,828 | ||
ROIC | |||||
ROCE | 5,675.70% | ||||
| EV | |||||
Common stock shares outstanding | 13,640 | 11,505 | 1,941 | ||
Price | 0.79 -35.66% | 1.22 -50.41% | 2.46 | ||
Market cap | 10,708 -23.71% | 14,036 193.95% | 4,775 | ||
EV | 8,330 | 7,345 | (4,460) | ||
EBITDA | (12,049) | (13,552) | (5,584) | ||
EV/EBITDA | 0.80 | ||||
Interest | 550 | 15 | 1,154 | ||
Interest/NOPBT | |||||